1Joseph K and Roger JP. Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy[J]. Clin infect dis, 2002,35(15 Dec) : 1520 - 1526.
2Lu W, Andrieu J-M. In vitro human immunodeficiency virus eradication by autologous CD8 T cells expanded with inactivated-virus-pulsed dendritic cells[ J ]. J Virol, 2001,75 : 8949 - 56.
3Karlsson AC, Birk M, Lindback S, Initiation of therapy during prima-ry HIV type 1 infection results viral evolution[J]. AIDS Res Hum Retroviruses, 2001,17:409 - 16.
4Imarniehi H, Crandall KA, Natarajan V, et al. Human immunodefieieney virus type 1 quasi speeies that rebound after discontinuation of highly aetive antiretroviral therapy are similar to the viral quasi speeies present before intiation of therapy[J]. J Infeet Dis, 2001,183:36 - 50.
5Sonza S, Mutimer FIP,Oelriehs R, et al. Monocytes harbour replication-compentent non-latent HIV-1 in patients on highly aetive antiretroviral therapy[J]. AIDS,2001,15 : 17 - 22.
6Pomerantz RI. Residual HIV-1 infection during antiretroviral therapy: the challenge of viral persistence[ J ]. AIDS, 2001,15 : 1201 - 11.
7Lafeuillad A, Poggi C, Chadapaud S, et al. Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission[J] .J Acquit Immun Defic Syndr,2001,26:44- 5.
8Sell S. Immunology, immunopathology and immunity[M]. 6th ed,Washington DC:American society for Microbiology Press,2001.
9Havlir DV,Gilbert PB,Bennett K, et al. Effects of treatment intesification with hydroxyurea in HIV-infected in patients with virologic suppression[J]. AIDS,2001,15 : 1379 - 88.
10Van Praag RME, Prins JM, Roos MT, et al. OKT3 and IL-2 treatment for purging of the latently infected CD4 T cells using a combination of cytokines[J]. Exp Med, 1998,188:83 - 91.
